Gastric dilatation-volvulus (GDV) or gastric dilatation (GD), were diagnosed in 173 dogs during the period from 1997 to 2001. Risk factors possibly associated with higher mortality in cases of GDV were evaluated. Variables suitable for quantitative evaluation were examined by the Student's t-test with regard to the risk of death. We characterised groups of dogs with potential risk factors (age, body weight, time lapsed from the last feeding until presentation, time lapsed from the onset of clinical signs until presentation, time lapsed from the last feeding until the onset of clinical signs), and compared the groups with regard to the risk of death, using the χ 2 -test. There were no differences between the dying and surviving patients as to their age, body weight and time lapsed from the last feeding until the onset of clinical signs. The time lapsed from the onset of clinical signs until presentation at the clinic was a significant factor associated with a lower survival rate. Mortality in dogs with GDV was 26.3% (36/137). Significantly higher mortality (p < 0.01) was found in dogs with gastric necrosis. Gastric necrosis in dogs with GDV is responsible for a 6.5 times higher risk of death compared to patients without gastric necrosis. There was also higher mortality in dogs after splenectomy (p < 0.05). Results of our study suggest that the most important prognostic factor is a timely treatment following the onset of clinical signs of GDV.
Dog, retrospective study, gastric necrosis, splenectomy, risk factors, feedingGastric dilatation-volvulus (GDV) is a very serious, life-threatening syndrome typically affecting large and giant breeds of dogs. For example, in the United States of America this syndrome affects about 60 000 dogs a year (Burrows and Ignaszewski 1990). The risk of this syndrome in some dog breeds is very high. In the Great Dane it amounts to more than 40% (Glickman et al. 2000). Despite its recognition more than 90 years ago (Cadeac 1906) and considerable advances in diagnosis and treatment, mortality associated with GDV still remains high. Various studies report mortality varying from 10 to 60% (Betts et al. 1974;Muir 1982;Walshaw and Johnson 1976;Matthiesen 1983;Frankquist and Obel 1979; Winfgield et al. 1975;Glickman et al. 1994;Brockman et al. 1995;Brourman 1996;Van Sluijs 1991;Glickman et al. 1998;Eggertsdóttir and Moe 1995;Nagel and Neumann 1992). It is, however, difficult to compare individual results because of differences in the definition of mortality and different therapeutic procedures within individual studies.On the basis of our current knowledge, therapy of the syndrome consists of three important parts:1) immediate and aggressive patient stabilisation including gastric decompression and treatment of shock; 2) surgical correction of volvulus including gastropexy to prevent recurrence; and 3) post-operative monitoring and intensive care (Matthiesen 1983;Aronson et al.